D2V Clinical

Tech firm Clario is boosting its electronic clinical outcome assessment (eCOA) offerings by

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have

Montreal-based CRO Innovaderm Research has rebranded immediately to In | Montreal-based CRO Innovaderm Research has rebranded with immediate effect to Indero, the latest change in an effort to become dually focused on both rheumatology and dermatology.

?? AI is Transforming Clinical Trials – But Humans Are Still the Key Not long ago, drug development was a slow, costly process, often taking a decade or more to bring a new treatment to market. But in 2024, AI is changing the game—and fast. We’re seeing AI step in as a powerful ally in clinical research, helping scientists discover new drugs, recruit patients faster, and analyze trial data more accurately than ever before. Here’s What’s Happening Right Now: ? AI is speeding up drug discovery – What used to take years can now happen in months. AI models can scan massive datasets to identify promising compounds in record time. ? Finding the right patients is getting easier – AI is analyzing electronic health records to match the right patients with the right trials, reducing recruitment bottlenecks. ? Real-time patient monitoring is a game changer – Wearable devices powered by AI track patient health and flag issues before they become serious. ? Predicting trial outcomes is now possible – AI can analyze past clinical data to forecast risks, side effects, and effectiveness, making trials smarter and safer. But let’s be real—AI can’t run clinical trials alone. It still needs human oversight, ethical judgment, and medical expertise. AI can identify patterns, but it takes scientists, doctors, and regulators to make sense of them. AI can predict risks, but it’s human decision-making that runs a trial and CRO to ensures patient safety. Technology is only as good as the people guiding it. The future isn’t AI replacing humans—it’s humans using all the tools available to bring life-saving treatments to patients faster and safer than ever before. What do you think? Will AI revolutionize clinical trials, or is human expertise still the most important factor? Let’s discuss. ?? #AI #ClinicalTrials #HealthcareInnovation #DrugDiscovery #FutureOfMedicine #HumanInTheLoop

?? Why Small CROs Are Game-Changers in Clinical Research In a world dominated by large Contract Research Organizations (CROs), boutique CROs like D2V Clinical offer something different—agility, flexibility, and a truly personalized approach to clinical trials. ?? What sets small CROs apart? ? Speed & Adaptability – Less bureaucracy means faster decision-making and the ability to pivot quickly when challenges arise. ? Personalized Service – Clients work directly with senior experts, ensuring tailored solutions and dedicated attention. ? Stronger Partnerships – We prioritize collaboration over volume, meaning our sponsors get more engaged, responsive teams who deeply understand their needs. ? Focused Expertise – Boutique CROs specialize in specific therapeutic areas, offering deep insights and hands-on experience. At D2V Clinical, we believe that size doesn’t define impact—commitment, expertise, and agility do. ?? Looking for a CRO that moves fast, thinks smart, and delivers with precision? Let’s talk: D2VClinical.com ?? What do you value most in a CRO partnership? Drop your thoughts below! ?? #ClinicalResearch #CRO #ClinicalTrials #Biotech #LifeSciences #AgileCRO

Global contract research organization IQVIA is looking to simplify workflows for its clinical trial investigators with a new bundle of digital applications. | Global contract research organization IQVIA is looking to simplify workflows for its...

Private equity giant Blackstone is going big on Japan,

Diabetic Foot Ulcers: A Silent Epidemic in Need of Innovation Diabetic foot ulcers (DFUs) are more than just wounds—they’re a global health crisis. ???? ?? Key Facts: ? 25% of diabetics will develop a foot ulcer in their lifetime. ? Up to 85% of amputations due to diabetes begin with a foot ulcer. ? Early intervention & research can significantly improve outcomes. Yet, despite these numbers, clinical research in DFUs is often underfunded and overlooked. ?? The Future of DFU Research Breakthroughs in regenerative medicine, advanced wound therapies, and AI-driven diagnostics are reshaping treatment strategies. That’s why D2V is conducting a groundbreaking DFU study—pushing the boundaries of regenerative medicine, AI-driven diagnostics, and advanced wound therapies. But we need more patient enrollment, greater awareness, and accelerated trials to drive change. ?? How can we, as an industry, prioritize DFU research? Let’s discuss! Drop your insights below ?? #ClinicalResearch #DiabeticFootUlcers #DiabetesCare #ClinicalTrials #InnovationInMedicine

Clinical trial matchmaker myTomorrows has struck up a partnership with personal health recordkeeper Patients Know Best (PKB) so that U.K. participants can search for possible trials to join. | Clinical trial matchmaker myTomorrows has struck up a...

Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the government and beyond, several large drugmakers say running diverse clinica | Even as President Donald Trump wages a very public...